122 related articles for article (PubMed ID: 24991313)
1. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers.
Greenapple R
Am Health Drug Benefits; 2012 Mar; 5(2):83-92. PubMed ID: 24991313
[TBL] [Abstract][Full Text] [Related]
2. Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.
Greenapple R
Am Health Drug Benefits; 2012 Jul; 5(4):242-53. PubMed ID: 24991323
[TBL] [Abstract][Full Text] [Related]
3. The evolution of payer management of oncology drugs in the United States between 2017 and 2022.
Runyan A; Yi J; Honcz J
J Manag Care Spec Pharm; 2023 Oct; 29(10):1138-1149. PubMed ID: 37695273
[No Abstract] [Full Text] [Related]
4. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
5. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.
Atzinger CB; Guo JJ
Am Health Drug Benefits; 2017 Feb; 10(1):27-36. PubMed ID: 28465766
[TBL] [Abstract][Full Text] [Related]
6. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
7. Obesity: effective treatment requires change in payers' perspective.
Greenapple R; Ngai J
Am Health Drug Benefits; 2010 Mar; 3(2):88-94. PubMed ID: 25126310
[TBL] [Abstract][Full Text] [Related]
8. Rapid expansion of new oncology care delivery payment models: results from a payer survey.
Greenapple R
Am Health Drug Benefits; 2013 Jul; 6(5):249-56. PubMed ID: 24991361
[TBL] [Abstract][Full Text] [Related]
9. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
10. Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis.
Glauser TA; Ruderman EM; Kummerle D; Kelly S
Rheumatol Ther; 2014 Dec; 1(1):31-44. PubMed ID: 27747761
[TBL] [Abstract][Full Text] [Related]
11. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making.
Bolge SC; Goren A; Brown D; Ginsberg S; Allen I
Patient Prefer Adherence; 2016; 10():1079-90. PubMed ID: 27390518
[TBL] [Abstract][Full Text] [Related]
12. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Insurance companies' perspectives on the orphan drug pipeline.
Handfield R; Feldstein J
Am Health Drug Benefits; 2013 Nov; 6(9):589-98. PubMed ID: 24991385
[TBL] [Abstract][Full Text] [Related]
15. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
17. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
18. Impact of the removal of the monthly liver function test requirement for ambrisentan.
Durst LA; Carlsen J; Kuchinski M; Harner L; Neves D; Harris SJ; Traiger GL
Am Health Drug Benefits; 2012 Mar; 5(2):94-101. PubMed ID: 24991314
[TBL] [Abstract][Full Text] [Related]
19. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
20. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
